Peptides are coming
Feb 08 2017 , Mr. Nachiket Ghumare
Anti-infective Peptides Market to Benefit from Elevated Research Initiatives from Key Companies
Posted via Industry Today
“The global anti-infective peptides market is driven by the increasing resistance of pathogens to drugs currently available in the market. The overuse of antifungal, antibacterial, and antiviral drugs has led to a high level of drug resistance in several key pathogen groups. This has led firms in the global peptides market to seek innovative products that will overcome this key challenge.
Peptides are extensively used in biotechnology and medicine. They act as an endocrine signal or a neurotransmitter for regulation of most physiological processes. Peptides are being examined as having the potential to treat several medical conditions such as diabetes. At present, there are 60 peptide drugs approved by the U.S. Food and Drug Administration (FDA). Furthermore, the use of peptides to treat various infections is currently rising and several key players in the market are involved in these initiatives.”
“In the past few years, phage display technologies were deployed to create monoclonal antibodies targeted against inflammatory or cancer disease targets. Furthermore, patent disputes impeded the broad use of this technology and contributed to the dearth of candidates during the 1990s. However, phase display technology is now recognized as a powerful tool for choosing novel peptides and antibodies capable of binding to a wide range of antigens from whole cells to proteins and lipid targets. This technology to discover novel therapeutics for infectious conditions will further boost the global anti-infective peptides market. Furthermore, improvement in manufacturing, screening, and humanization methods will in turn make a significant contribution to the development of peptides.”
There is no clinical tryout at the moment of MuTaTo in Israel or outside of Israel.Contact us at email@example.com
Our team are research scientists (Ph.D.) and are not attending Dr.
We are working now for the 20th year entering our 21th year of R&D effort (in June 2022).
We don’t have a Clinique and we can not advise nor refer to any specific case.
We initially intend to target: lung, colon, head & neck cancers.
The treatment, in any case, has to be individually adapted to the patient.
We are a small team and have an influx of e-mail.
We try to answer at least initial emails but can not promise it.
This website may contain certain statements, estimations, projections, assessments and other information with respect to the anticipated future performance of the Company and/or its market and involve risks and uncertainties. Actual results or future business decisions of the Company may differ materially from any expectations, projections or predictions made or implicated in statements made in this website. While the Company believes that the information contained herein is accurate, it expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this website or any other communication transmitted or made available herein. Any prospective website user acknowledges his/her responsibility to perform a due diligence review prior to consummating a transaction with the Company. Included in this website are certain declarations by the Company with respect to its anticipated future performance. These declarations are based on estimates and assumptions by the Company that are subject to economic and competitive uncertainties beyond the control of the Company. The Company does not provide representation or warranty with regard to the declarations and there can be no assurance that the future results will be realized or that actual results will not be significantly different from those projected. The Company is not obligated to update or revise any future declarations. The Company and its respective affiliates, directors, officers, employees, consultants and representatives expressly disclaim any and all liability relating to or resulting from the utilization of any information contented in this website. The Company does not have any obligation to provide with access to additional information.